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Abstract
Background: Coronary heart disease (CHD) in premenopausal women is rare. This may be
related to the protective effect of endogenous estrogens on the female cardiovascular system. The
aim of the study was to analyse the levels of sex hormones in premenopausal women with CHD
confirmed by coronary angiography.
Methods: Thirty women aged 34–53 years and with a mean age of 46.3 ± 5.2 years were
enrolled in the study. All were regularly menstruating, in the premenopausal period (i.e. with
FSH < 15 IU/L and FSH > LH), with stable CHD and with significant atherosclerotic
plaques in coronary angiography (narrowings > 50% of the lumen diameter). Of these, 80%
had myocardial infarction in their histories. Estradiol plasma levels and gonadotrophic hor-
mone (luteinising hormone LH and follicle-stimulating hormone FSH) plasma levels were
measured in the women under investigation.
Results: A diminished estradiol level was diagnosed in 14 patients (46.7%) of the 30 pre-
menopausal women examined (patients with hypoestrogenemia). In 12 women (40%)
hypoestrogenemia was accompanied by diminished levels of gonadotrophins (hypo-
estrogenaemia of hypothalamic origin).
Conclusion: The plasma estradiol level was diminished in 46.7% of premenopausal women
with CHD. Insufficient level of endogenous estradiol could have contributed to the early devel-
opment of atherosclerotic plaques in the epicardial coronary arteries of the women examined.
(Folia Cardiol. 2006; 13: 423–426)
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Introduction
Diseases of the cardiovascular system are re-
sponsible for a majority of deaths and cause sub-
stantial morbidity among Polish women. According
to statistical data, 57.1% of deaths in women above
25 years of age are caused by diseases of the heart
and vessels [1, 2].
Coronary heart disease (CHD) is infrequently
diagnosed in premenstrual women [1], what could
be related to the protective influence of endogenous
estrogens on the feminine cardiovascular system.
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Estrogens, through their membrane receptor (the
non-genomic effect), stimulate the immediate re-
lease of nitrate oxide from endothelial cells, which
results in vasodilatation [3]. Moreover, estrogens
partially block type L calcium channels [4] and cau-
se an opening of the potassium channels in the va-
scular smooth muscle cells [5], which also promo-
tes vasodilatation. Estrogens, through their intra-
cellular receptors, affect gene expression (the
genomic effect). Through this mechanism they in-
crease synthesis of nitric oxide and prostacycline
as well as augment expression of the atrial natiure-
tic peptide (ANP) gene [6]. Furthermore, estrogens
have a favourable effect on the plasma lipid profile
by lowering the level of low-density lipoprotein
cholesterol (LDL) through the up-regulation of their
receptors, raising the level of high density lipopro-
tein cholesterol (HDL) and decreasing lipoprotein
(a) level [7]. Estrogens lower the fibrinogen level
and stimulate fibrinolysis by reducing plasminogen
activator inhibitor-1 (PAI-1). They improve glucose
metabolism and decrease serum insulin level [8]. Es-
trogens show antioxidant properties, accelerate en-
dothelial cell regeneration after mechanical injury
and improve endothelial function, which results in
increased hyperaemic vasodilatation [8]. Estrogens
decrease proliferation of the vascular smooth mu-
scle cells and inhibit apoptosis of the endothelial
cells [9]. Moreover, experimental data confirm the
presence of estrogen receptors in the central ne-
rvous system in the nuclei of the autonomic nervo-
us system and in the peripheral nerve endings [10]
Estrogens increase synthesis and release of acetyl-
choline on every level of the autonomic nervous
system and thus contribute to the relative predo-
minance of the parasympathetic nervous system in
women [10].
Little published work is available on sex hor-
mone levels in menstruating women with CHD. The
results of two papers indicate a lower estradiol le-
vel in premenopausal women with diagnosed CHD
compared to healthy women [11, 12]. Other authors
do not confirm this association [13, 14].
In view of the divergent results of the former
papers we performed an analysis of the sex hormo-
ne levels in premenopausal women with angiogra-
phically proven CHD.
Methods
Thirty women aged 34–53 years and with
a mean age of 46.3 ± 5.2 years were enrolled in the
study. All were regularly menstruating, in the pre-
menopausal period (i.e. with FSH < 15 IU/L and
FSH > LH) and were hospitalized in the Depart-
ment of Coronary Heart Disease of the Institute of
Cardiology, Collegium Medicum Jagiellonian Uni-
versity and/or treated in the out-patient Cardiolo-
gical Department of the John Paul II Hospital.
The inclusion criteria were as follows:
— stable CHD diagnosed on the basis of anamne-
sis, non-invasive tests and coronary angiography;
— the presence of significant atherosclerotic pla-
ques (above 50% of the lumen diameter) in
coronary angiography;
— informed consent to participation in the study.
Estradiol plasma level and gonadothrophic hor-
mone (luteinising hormone LH and follicle-stimu-
lating hormone FSH) plasma levels were measured
in the women under investigation.
Estradiol, LH and FSH levels were measured
with electrochemiluminescence immunoassay
(ECLIA, Roche). Because of the proven functional
amenorrhoea in menstruating women with CHD,
measurements of the sex hormone levels were per-
formed on any day of the menstrual cycle [12]. Hy-
poestrogenemia was diagnosed if the estradiol pla-
sma level was below 50pg/ml and secondary hypo-
estrogenemia related to hypopituitarism was
diagnosed where coexisting LH and FSH levels fell
below 10mIU/ml  (hypoestrogenemia of hypothala-
mic origin) [12].
Statistical analysis was performed using the
STATISTICA for Windows software. Results were
shown as mean ± 1 standard deviation (SD) for
continuous data and proportions for categorical data.
In order to evaluate the normality of the data distri-
bution, the Shapiro-Wilk test was used. For normal
data distribution a t test was used. When data
distribution was not normal, non-parametric tests
were used (the Wald-Wolfowitz test, the Mann-Whit-
ney U test or the Kolmogorov-Smirnov test). A p va-
lue < 0.05 was considered statistically significant.
Results
Class III angina according to the CCS classifi-
cation was the most frequently encountered form
in the women examined, being observed in 15 pa-
tients (50%). Five women (16.7%) had class I angi-
na and 10 patients (33.3%) had class II angina.
Heart failure was found in 4 patients (13.3%). Heart
failure class I according to NYHA classification was
observed in 2 patients (6.7%), class II in 1 woman
(3.3%) and class III also in 1 woman (3.3%).
Twenty four patients (80%) had history of
myocardial infarction (MI). Fourteen patients
(46.7%) had a Q-wave MI and 10 patients (33.3%)
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had a non Q-wave MI. A majority of the patients
(21 women, 70.0%) had had 1 MI, while 3 patients
(10%) had had 2 MI.
Single-vessel disease was that most frequen-
tly encountered in the patients examined, being
found in 21 women (70%). Double-vessel disease
was diagnosed in 4 patients (13.3%) and triple-ves-
sel disease was present in 5 women (16.7%).
Eighteen patients (60%) underwent revascu-
larisation before enrolment to the study. Percuta-
neous transluminal coronary angioplasty was per-
formed in 17 patients  (56.7%). One woman under-
went coronary artery by-pass graft surgery.
Plasma estradiol levels in the women exami-
ned ranged from 10.05 to 143.60 pg/ml, with a mean
of 59.75 ± 15.86 pg/ml. LH plasma levels ranged
from 1.01 to 13.04 mIU/ml, with a mean of 5.88 ±
± 6.11 mIU/ml. FSH plasma levels ranged from 2.30 to
14.03 mIU/ml, with a mean of 6.82 ± 6.83 mIU/ml.
On the basis of the above analyses hypoestro-
genemia was diagnosed in 14 patients (46.7%).
Twelve women (40%) had both hypoestrogenemia
and diminished levels of gonadotrophins. These
were patients with secondary hypoestrogenemia
related to hypopituitarism (hypoestrogenemia of
hypothalamic origin).
Discussion
Hypoestrogenemia was found in nearly half the
examined premenopausal women with CHD. A di-
minished estradiol level was related to low gona-
dotrophin levels in 12 out of 14 women with hypo-
estrogenemia. These patients were diagnosed with
hypoestrogenemia of hypothalamic origin.
Little published work is available which evalu-
ates sex hormone levels in premenopausal women
with CHD. The results of WISE (Women’s Ischa-
emia Syndrome Evaluation) study indicate signifi-
cantly lower estradiol and FSH levels in premeno-
pausal women with significant atherosclerotic pla-
ques in coronary angiography compared to
premenopausal women with chest pain and normal
coronary angiography [12]. Hypoestrogenemia of
hypothalamic origin was found in 9 out of 13 wo-
men (70%) with CHD and critical atherosclerotic
plaques in coronary angiography compared to 30%
of women without coronary atherosclerosis [12].
Moreover, hypoestrogenemia of hypothalamic ori-
gin was an independent marker of critical narro-
wings in the epicardial coronary arteries in preme-
nopausal women with chest pain [12]. Other works
have demonstrated lower plasma estradiol levels in
menstruating women with a history of MI compa-
red to healthy women [11]. However, Malczewska
et al. [13] found no significant differences in sex
hormone levels in menstruating women with and
without significant atherosclerotic plaques in coro-
nary angiography.
Hypoestrogenemia leads to endothelial dys-
function. Hashimoto et al. [15] examined endothe-
lial function in three phases of the menstrual cycle
in healthy women and found endothelium-depen-
dent vasodilatation to be greatest during the folli-
cular and luteal phases of the menstrual cycle, tho-
se phases in which the level of estradiol is high [15].
Endothelial dysfunction was also found in postme-
nopausal women with CHD. Intracoronary infusion
of acetylcholine to the atherosclerotic coronary ar-
teries of postmenopausal women caused vasocon-
striction [16]. Intracoronary administration of es-
tradiol before infusion of acetylcholine normalised
endothelial function and vasodilatation following
acetylcholine infusion has been observed [16]. In
other studies it was found that sublingual estradiol
diminished the intensity of ischaemia in the exer-
cise treadmill test in postmenopausal women with
CHD [17]. Furthermore, the anti-atherosclerotic
effect of estradiol has been demonstrated by experi-
mental data. Oral estradiol supplementation delay-
ed the development of atheroclerosis in castrated
simian females fed with a cholesterol-rich diet [18].
Randomised prospective studies in postmeno-
pausal women do not confirm the favourable effect
of oral estradiol supplementation on the formation
and progression of atherosclerotic plaques [19–21].
Only the results of EPAT (Estrogen in the Preven-
tion of Atherosclerosis Trial) indicate that in post-
menopausal women with elevated LDL-cholesterol
levels the intima-media thickness of the common
carotid artery decreases in patients on oral estra-
diol supplementation and increases in women re-
ceiving placebo [22].
Analysis of trials which evaluate the effect of
oral estradiol supplementation in postmenopausal
women necessitates consideration of the means by
which estradiol is to be administered. The effect of
endogenous estradiol or estradiol administered pa-
renterally cannot be compared with oral estradiol
supplementation [8]. Estradiol secreted in the ova-
ries or administered parenterally enters the syste-
mic circulation directly. Estradiol administered oral-
ly through the portal circulation reaches the liver
at a high concentration and is metabolised to inac-
tive metabolites (the first-pass effect) [8]. The dose
of orally administered estradiol required to obtain
a physiological plasma estradiol level is 10 times
higher than the equivalent dose of parenterally-
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-administered estradiol [8]. These high estradiol levels
influence the hepatic metabolism of other substan-
ces such as apolipoproteins, proteins of the coagu-
lation system and C-reactive protein, which has
a prothrombotic and proinflammatory effect with
consecutive progression and destabilisation of the
atherosclerotic plaques [8].
The results of this study indicate the high inci-
dence of hypoestrogenemia in premenopausal wo-
men with stable CHD. Insufficient levels of endoge-
nous estradiol may have contributed to the early
development of atherosclerotic plaques in the epi-
cardial coronary arteries of the women examined.
In conclusions, plasma estradiol levels were
diminished in 46.7% of premenopausal women with
coronary heart disease. Insufficient level of endo-
genous estradiol could have contributed to the ear-
ly development of atherosclerotic plaques in the
epicardial coronary arteries of the women under
investigation.
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